| Literature DB >> 31383375 |
Qian Chu1, Tina Chang1, Alan Saghatelian2.
Abstract
Enzymes with multiple substrates pose a unique challenge for drug development because of an increased potential for on-target side effects. Maianti and colleagues (Nat. Chem. Biol., 2019) identify novel exo-site inhibitors with abilities to alter the substrate-selectivity of insulin-degrading enzymes (IDE). Their work illuminates new therapeutic avenues for discovering small-molecule enzyme inhibitors and redefines our current understanding of drugging enzymes with multiple substrates.Entities:
Keywords: chemical biology; enzyme reprogramming; exo site; insulin-degrading enzyme; substrate-selective inhibition
Mesh：
Substances：
Year: 2019 PMID： 31383375 DOI： 10.1016/j.tips.2019.07.009
Source DB: PubMed Journal: Trends Pharmacol Sci ISSN： 0165-6147 Impact factor: 14.819